Combination of human fas (CD95/Apo-1) ligand with adriamycin significantly enhances the efficacy of antitumor response

Cellular and Molecular Immunology

Volumn 6, Issue 3, 2009, Pages 167-174

  Liu, Zhongchen ^a   Liu, Ruizhen ^a   Qiu, Jinhua ^a   Yin, Ping ^a   Luo, Fanghong ^a   Su, Jinhua ^a   Li, Wenzhu ^a   Chen, Caixia ^a   Fan, Xin ^a   Zhang, Jiakai ^a   Zhuang, Guohong ^a  

^a XIAMEN UNIVERSITY   (China)

Author keywords

ADM; Apoptosis; Combination therapy; FasL; Hepatocellular carcinoma

Indexed keywords

DOXORUBICIN; FAS LIGAND; RECOMBINANT PROTEIN; ANTINEOPLASTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GRAFT; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MALE; MOUSE; NICK END LABELING; NONHUMAN; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECT; FLOW CYTOMETRY; GENETICS; LIVER; LIVER TUMOR; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR VOLUME; ANIMAL CELL; CANCER CELL DESTRUCTION; DRUG EFFICACY;

MURINAE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG SYNERGISM; FAS LIGAND PROTEIN; FEMALE; FLOW CYTOMETRY; HUMANS; LIVER; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, INBRED BALB C; RECOMBINANT PROTEINS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 68549106174     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2009.23     Document Type: Article

References (31)

1. Liu H, Pan ZY, Li AJ, et al. Roles of chemokine receptor 4 (CXXR4) and chemokine ligand 12 (CXCL12) in metastasis of hepatocellular carcinoma cells. Cell Mol Immunol. 2008;5:373-378.
2. Payne AS, Cornelius LA. The role of chemokines in melanoma tumor growth and metastasis. J Invest Dermatol. 2002;118:915-922. (Pubitemid 34639168)
3. Tang ZY. Hepatocellular carcinoma-cause, treatment and metastasis. World J Gastroenterol. 2001;7:445-454.
4. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 1993;75:1169-1178. (Pubitemid 24006113)
5. Wallach D, Varfolomeev EE, Malinin N, et al. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol. 1999;17:331-367. (Pubitemid 29241128)
6. Suda T, Okazaki T, Naito Y, et al. Expression of the Fas ligand in cells of T cell lineage. J Immunol. 1995;154:3806-3813.
7. Montel AH, Bochan MR, Hobbs JA, et al. Fas involvement in cytotoxicity mediated by human NK cells. Cell Immunol. 1995;166:236-246.
8. Bellgrau D, Gold D, Selawry H, et al. A role for CD95 ligand in preventing graft rejection. Nature. 1995;377:630-632.
9. Griffith TS, Brunner T, Fletcher SM, et al. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 1995;270:1189-1192.
10. Uckan D, Steele A, Cherry, et al. Trophoblasts express Fas ligand: a proposed mechanism for immune privilege in placenta and maternal invasion. Mol Hum Reprod. 1997;3:655-662. (Pubitemid 127509722)
11. Strand S, Hofmann WJ, Hug H, et al. Lymphocyte apoptosis induced by CD95/(APO-1/Fas) ligand-expressing tumor cells- a mechanism of immune evasion? Nat Med. 1996;2:1361-1366.
12. Hahne M, Rimoldi D, Schroeter M, et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science. 1996;274:1363-1366. (Pubitemid 26391458)
13. Nagata S, Golstein P. The Fas death factor. Science. 1995;267:1449-1456.
14. Tanaka M, Itai T, Adachi M, Nagata S. Downregulation of Fas ligand by shedding. Nat Med. 1998;4:31-36.
15. Kayagaki N, Kawasaki A, Ebata T, et al. Metalloproteinase-mediated release of human Fas ligand. J Exp Med. 1995;182:1777-1783.
16. Mitsiades N, Yu WH, Poulaki V, et al. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res. 2001;61:577-581. (Pubitemid 32128617)
17. Tanaka M, Suda T, Takahashi T, Nagata S. Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J. 1995;14:1129-1135.
18. Roskams T, Libbrecht L, Van Damme B, Desmet V. Fas and Fas ligand: strong co-expression in human hepatocytes surrounding hepatocellular carcinoma; can cancer induce suicide in peritumoral cells? J Pathol. 2000;191:150-153.
19. Fukuzawa Y, Takahashi K, Furuta K, et al. Expression of Fas/Fas ligand (FasL) and its involvement in infiltrating lymphocytes in hepatocellular carcinoma (HCC). J Gastroenterol. 2001;36:68l-688. (Pubitemid 33040941)
20. Lee SH, Shin MS, Lee HS, et al. Expression of Fas and Fas-related molecules in human hepatocellular carcinoma. Hum Pathol. 2001;32:250-256. (Pubitemid 32246797)
21. Schneider P, Holler N, Bodmer JL, et al. Conversion of membrane-bound Fas (CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med. 1998;187:1205-1213. (Pubitemid 28189110)
22. Suda T, Hashimoto H, Tanaka M, et al. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med. 1997;186:2045-2050. (Pubitemid 28013689)
23. Rensing-Ehl A, Frei K, Flury R, et al. Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur J Immunol. 1995;25:2253-2258.
24. Tanaka M, Suda T, Yatomi T, et al. Lethal effect of recombinant human Fas ligand in mice pretreated with propionibacterium acnes. J Immunol. 1997;158:2303-2309. (Pubitemid 127470015)
25. Tanaka M, Suda T, Haze K, et al. Fas ligand in human serum. Nat Med. 1996;2:317-322.
26. Bayona-Bafaluy MP, Manfredi G, Moraes CT. A chemical enucleation method for the transfer of mitochondrial DNA to rho (o) cells. Nucleic Acids Res. 2003;31:98.
27. Reed JC. Double identity for proteins of Bcl-2 family. Nature. 1997;387:773-776.
28. Nagata S. Apoptosis by death factor. Cell. 1997;88:355-365.
29. 2- and p53-dependent pathways. J Biol Chem. 2004;279:25535-25543.
30. Kumar D, Jugdutt BI. Apoptosis and oxidants in the heart. J Lab Clin Med. 2003;142:288-297.
31. Muller I, Niethammer D, Bruchelt G. Antrhacycline derived chemotherapeutics in apoptosis and free radical cytotoxicity. Int J Mol Med. 1988;1:491-494.